ISHLT Consensus Document on Lung Transplantation in Patients with Connective Tissue Disease: Part I

Published 28 July 2021

Maria M. Crespo, MD; Erika D. Lease, MD; Amparo Sole, MD, PhD; Nora Sandorfi, MD; Laurie D. Snyder, MD; Gerald J. Berry, MD; Jérôme Le Pavec, MD, PhD; Aida E. Venado, MD; Jose M. Cifrian, MD; Hilary Goldberg, MD; Daniel F. Dilling, MD; Cynthia Gries, MD; Arun Nair, MD; Keith Willie, MD, MSPH; Keith C. Meyer, MD; Rupal J. Shah, MD; Sofya Tokman, MD; Are Holm, MD; Caroline M. Patterson, MD; Tanya McWilliams, MD; Osnat Shtraichman, MD; Brad Bemiss, MD; Juan Salgado, MD; Carol Farver, MD; Heather Strah, MD; Katharina Wassilew, MD, DSmed; Vaidehi Kaza, MD, MPH; Molly Howsare, DO; Michelle Murray, MD; Sangeeta Bhorade, MD; Marie Budev, DO

J Heart Lung Transplant. 2021 Nov; 40(11):1251-1266

• Advanced Lung Failure & Transplantation
• Anesthesiology & Critical Care
• Cardiothoracic Surgery
• Consensus Document
• Infectious Diseases
• Nursing & Allied Health
• Pathology
• Pediatrics
• Pharmacy
• Publications & Journals
• Pulmonology
• Research & Immunology
• Standards & Guidelines

Patients with connective tissue disease (CTD) and advanced lung disease are often considered suboptimal candidates for lung transplantation (LTx) due to their underlying medical complexity and potential surgical risk. There is substantial variability across LTx centers regarding the evaluation and listing of these patients.

The goals of this consensus paper are to clarify definitions of each disease state included under the term CTD, to describe the extrapulmonary manifestations of each disease requiring consideration prior to transplantation, and to outline the absolute contraindications to transplantation as determined by a Delphi consensus methodology. The purpose of this effort is to allow for risk stratification during the evaluation and selection of candidates for LTx and heart-lung transplantation (HLTx).

Read at JHLT

Download Figures